Pharmaceuticals firm Lupin Ltd on Friday said it has received the establishment inspection report from the US Food and Drug Administration (USFDA) for its new injectable facility located in Nagpur. The establishment inspection report (EIR) was issued after the last inspection of the facility conducted from October 17-29, 2022, the company said in a regulatory filing.

The injectable facility at Nagpur is designed to the highest quality standards and adheres to international regulations with advanced technology and equipment, Lupin Managing Director Nilesh Gupta said.

“We are committed to bringing an important portfolio of injectables addressing unmet needs from the facility,” he added.